

Prof. Dr. H. Döhner

Dr. Döhner is Professor of Medicine and Medical Director of the Department of Internal Medicine III, University Hospital of Ulm and Director of the Comprehensive Cancer Center Ulm. He is an expert in the conduct of clinical trials and in the identification, characterization and clinical diagnosis of genetic changes in hematologic malignancies, including both acute and chronic leukemias as well as malignant lymphoma. Dr. Döhner holds multiple leadership positions in the national and international scientific community of hematology/oncology including Board Member of the Competence Network “Acute and Chronic Leukemias”; Lead Participant of the European LeukemiaNet (funded by the European Union), Head of the German-Austrian AML Study Group (AMLSG); Board Member of the German Chronic Lymphocytic Leukemia Study Group (DCLLSG); member of the Scientific Committee of the International Working Group in CLL (IWCLL); member of the Clinical Advisory Committee of the WHO Classification of Hematopoietic and Lymphoid Neoplasms 2008; and member of the Myeloid Neoplasia Committee of the American Society of Hematology. [July 2012]

Current Positions:

- Medical Director, Department of Internal Medicine III (Hematology, Oncology, Rheumatology, and Infectious Diseases), University Hospital Ulm, Ulm, Germany
 - Director, Comprehensive Cancer Center Ulm (CCCU)
 - Coordinator, Collaborative Research Center (SFB) 1074 ‘Experimental models and clinical translation in leukemia’
-

Place of Birth:

Bad Kreuznach, Germany

University Education:

1976-1977	University of Regensburg Medical School, Regensburg, Germany
1977-1979	University of Freiburg Medical School, Freiburg, Germany
1979-1980	One year scholarship at the University of Montpellier Medical School, Montpellier, France
1980-1983	University of Freiburg Medical School, Freiburg

Degrees:

1983	<i>Doctor of Medicine</i> , University of Freiburg Medical School, Freiburg, Germany
1994	<i>Private Dozent (Habilitation)</i> , University of Heidelberg Medical School, Heidelberg, Germany
1999	<i>Professor of Medicine</i> , University of Ulm

Board Certification

1993	Internal Medicine
1998	Hematology and Oncology

Professional Experience:

1983-1985	Residency in Surgical Pathology, Institute of Pathology, St. Vincentius-Krankenhäuser (Prof. H.M. Schneider, Dr. H. Wolfmüller), Karlsruhe, Germany
-----------	---

1985-1988	Training in Internal Medicine / Hematology/Oncology, Medizinische Klinik and Poliklinik V (Prof. W. Hunstein), University of Heidelberg, Germany
1988-1990	Postdoctoral Associate in the Department of Medicine, Division of Oncology (Prof. Clara D. Bloomfield), and the Department of Laboratory Medicine and Pathology, Division of Medical Genetics (Prof. Diane C. Arthur), University of Minnesota, Minneapolis, MN, USA
1990-1993	Training in Internal Medicine / Hematology/Oncology, Medizinische Klinik and Poliklinik V (Prof. W. Hunstein), University of Heidelberg, Germany
1993-1999	<i>Oberarzt</i> , Division of Hematology/Oncology and Rheumatology; Department of Medicine (Director Prof. Dr. W. Hunstein; since 1997: Prof. A.D. Ho), University of Heidelberg, Heidelberg, Germany
2003-2011	Director, Department of Medicine, University Hospital Ulm
Since 1999	Medical Director, Department of Internal Medicine III, University of Ulm Medical Center
Since 2006	Director, Comprehensive Cancer Center Ulm (CCCU)

Memberships

1993	American Society of Hematology
1996	German Society of Hematology/Oncology
2001	European Hematology Association
2002	American Society of Clinical Oncology
2006	Deutsche Krebsgesellschaft

Awards

1979-80	Scholar, Deutscher Akademischer Austauschdienst
1988-90	Research Scholar, Mildred Scheel Stiftung
1995	Leukemia Clinical Research Award of the German Society of Hematology/Oncology
2009	Recipient of the Kenneth McCredie Lectureship, International Association for Comparative Research on Leukemia and Related Disorders (IACRLRD), Ohio, USA
2010	Anita- and Cuno-Wieland Research Award for Translational Cancer Research, University of Heidelberg
2011	Wilhelm-Warner Award for Cancer Research, Hamburg

Review for Journals and Organisations

- Annals of Hematology
- Blood
- European Journal of Immunology
- Genes Chromosomes and Cancer
- Haematologica/The Hematology Journal
- International Journal of Cancer
- Journal of Clinical Oncology
- Lancet
- Leukemia

- New England Journal of Medicine
- Associazione Italiana per la Ricerca sul Cancro
- Boehringer Ingelheim Foundation
- Deutsche Forschungsgemeinschaft
- Deutsche Krebshilfe
- Elke Kröner Fresenius Stiftung
- German-Israeli Foundation for Scientific Research and Development
- Medical Research Council, London, England
- Wilhelm-Sander Stiftung

Board / Committee Member

- Comprehensive Cancer Center Ulm (CCCU)
- Kompetenznetz “Acute and Chronic Leukemias”
- Scientific Committee of the *International Workshop of Chronic Lymphocytic Leukemia* (IWCLL)
- Elected Member (2004-2008), “Fachkollegium Medizin”, Deutsche Forschungsgemeinschaft
- Member, Leukemia Correlative Science Committee, Cancer and Leukemia Group B (CALGB), since 2006
- Member, Clinical Advisory Committee, WHO Classification of Hematopoietic and Lymphoid Neoplasms 2008
- Project Leader, Educational Committee, European Hematology Association (2005-2008)
- Member, Board (2003-2007), European Hematology Association (EHA)
- Member, Executive Board (2007-2012), European Hematology Association (EHA)
- Member, Hinterzartener Kreis für Krebsforschung, DFG (2008-2012)
- Elected Member, World Committee, International Association for Comparative Research on Leukemia and Related Disorders (IACRLRD) (2009-2013)
- Board of Directors, On-line Master Program “Advanced Oncology”, Ulm University
- Elected Member, Myeloid Neoplasia Committee, American Society of Hematology (2010-2013)
- Scientific Advisory Board, Center for Hematology and Regenerative Medicine (HERM), Karolinska Institute, Stockholm (since 2011)
- Appointed member, Haematology Working Group, Topic Advisory Group (TAG) for Internal Medicine, International Classification of Diseases (ICD), 11th edition (2011)

Invited Faculty (Selected International Meetings, since 2006)

- International Symposium Acute Leukemias XI, Munich, Germany, 2006
- European Bone Marrow Transplantation (EBMT) Meeting, Hamburg, 2006
- British Society of Haematology, Edinburgh, UK, 2006
- 2nd Mildred Scheel Cancer Conference, Bonn, Germany, 2006
- American Society of Clinical Oncology (ASCO), Atlanta, Georgia, USA, 2006
- 3rd International Meeting on “Innovative Therapies for Lymphoid Malignancies”, Palermo, Italy, 2006
- 9th CSH (Chinese Society of Hematology) Annual Meeting, Nanjing, China, 2006
- Réunion Scientifique du Groupe GCF-LLC/MW (French CLL Study Group, Paris, 2006
- 48th Meeting of the American Society of Hematology (ASH), Orlando, Florida, USA, 2006
- UK AML Forum, Birmingham 2007
- 4th Annual Symposium of the „European LeukemiaNet”, Heidelberg, 2007

- 23rd Annual Meeting of the Swedish Society of Hematology, Jönköping, Schweden, 2007
- 49th Meeting of the American Society of Hematology (ASH), Atlanta, Georgia, USA, 2007
- International Symposium Acute Leukemias XII, München, 2008
- 12th Annual Meeting of the European Hematology Association (EHA), Copenhagen, Denmark, 2008
- 50th Meeting of the American Society of Hematology (ASH), San Francisco, USA, 2008
- 40th Nordic Hematology Spring Meeting, Tampere, Finnland, Mai 2009
- 14th Congress of the European Hematology Association (Plenary Lecture), Berlin, Juni 2009
- 3rd Workshop on Acute Leukemia, Sinaia, Romania, October 2009
- IACRLRD (International Association for Comparative Research on Leukemia and Related Disorders) Symposium XXIV, Recipient of the Kenneth McCredie Lectureship, Ohio, USA, October 2009
- 51th Meeting of the American Society of Hematology (ASH), New Orleans, USA, 2009
- Deutscher Krebskongress (Plenary Lecture), Berlin, 2010
- European Association of Hematopathology, Uppsala 2010
- 12th Annual Scientific Meeting of the Haematology Society of Australia and New Zealand, Auckland, October 2010
- 16th Congress of the European Hematology Association, London, Juni 2011
- ESH-EHA Scientific Workshop on Acute Myeloid Leukemia “Molecular”, Mandelieu, France, October 2011
- XIV International Workshop on Chronic Lymphocytic Leukemia (iwCLL), Houston, USA, October 2011
- 53th Meeting of the American Society of Hematology (ASH), San Diego, USA, December 2011
- European School of Hematology (ESH) Updates in Clinical Hematology, Paris, France, February 2012
- Leopoldina Symposium ‘Molecular Diagnostics - Today and Tomorrow’, Venice International University, San Servolo, Italy, June 2012

Selected Publications:

2012

Gröschel S, Schlenk RF, Engelmann J, Rockova V, Teleanu V, Kühn WM, Eiwen K, Erpelinck C, Havermans M, Lübbert M, Germing U, Schmidt-Wolf IGH, Beverloo BH, Schuurhuis GJ, Ossenkoppele GJ, Schlegelberger B, Krauter J, Ganser A, Valk PJM, Löwenberg B, Döhner K, Döhner H*, Delwel R.* Deregulated expression of *EVI1* defines a poor prognostic subset of *MLL*-rearranged acute myeloid leukemias: a study of the German-Austrian AMLSG and Dutch-Belgian HOVON groups. **J Clin Oncol.** 2012, in press. *Equal contribution

Hoffmann S, Goetz M, Schneider V, Guiallaume P, Bunjes D, Döhner H, Wiesneth M, Greiner J. Donor lymphocyte infusion polyspecific CD8+ T cell responses with concurrent molecular remission in AML with NPM1 mutation. **J Clin Oncol.** 2012, in press.

Eisfeld AK, Marcucci G, Liyanarachchi S, Döhner K, Schwind S, Maharry K, Leffel B, Döhner H, Radmacher MD, Bloomfield CD, Tanner SM, de la Chapelle A. Heritable

polymorphism predisposes to high BAALC expression in acute myeloid leukemia. **Proc Natl Acad Sci U S A**. 2012;109(17):6668-73.

Dreger P, Döhner H, McClanahan F, Busch R, Ritgen M, Greinix H, Fink AM, Knauf W, Stadler M, Pfreundschuh M, Dührsen U, Brittinger G, Hensel M, Schetelig J, Winkler D, Bühler A, Kneba M, Schmitz N, Hallek M, Stilgenbauer S. Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the GCLLSG CLL3 trial. **Blood**. 2012 Apr 5. [Epub ahead of print]

Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Král Z, Fuchs M, Hallek M, Kanz L, Döhner H, Dörken B, Engel N, Topp M, Klutmann S, Amthauer H, Bokisch A, Kluge R, Kratochwil C, Schober O, Greil R, Andreesen R, Kneba M, Pfreundschuh M, Stein H, Eich HT, Müller RP, Dietlein M, Borchmann P, Diehl V; on behalf of the German Hodgkin Study Group, the Swiss Group for Clinical Cancer Research, and the Österreichische Arbeitsgemeinschaft für Klinische Pharmakologie und Therapie. **Lancet**. 2012 Apr 3. [Epub ahead of print]

Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gößele U, Koch B, Faber K, Genze F, Schrader M, Kestler HA, Döhner H, Chiosis G, Glimm H, Fröhling S,* Scholl C.* Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. **J Exp Med**. 2012;209(4):697-711. Epub 2012 Mar 26. *Equal contribution.

Gaidzik VI, Paschka P, Späth D, Habdank M, Köhne CH, Germing U, von Lilienfeld-Toal M, Held G, Horst HA, Haase D, Bentz M, Götze K, Döhner H, Schlenk RF, Bullinger L, Döhner K. TET2 mutations in acute myeloid leukemia (AML): Results from a comprehensive genetic and clinical analysis of the AML Study Group. **J Clin Oncol**. 2012 Mar 19. [Epub ahead of print]

Zenz T, Gribben JG, Hallek M, Döhner H, Keating MJ, Stilgenbauer S. Risk categories and refractory CLL in the era of chemoimmunotherapy. **Blood**. 2012 Mar 6. [Epub ahead of print]

Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, Fink AM, Bühler A, Zenz T, Wenger MK, Mendila M, Wendtner CM, Eichhorst BF, Döhner H, Hallek MJ, Kneba M. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: A multivariate analysis from the randomized GCLLSG CLL8 trial. **J Clin Oncol**. 2012;30(9):980-8. Epub 2012 Feb 13.

Rausch T, Jones DT, Zapatka M, Stütz AM, Zichner T, Weischenfeldt J, Jäger N, Remke M, Shih D, Northcott PA, Pfaff E, Tica J, Wang Q, Massimi L, Witt H, Bender S, Pleier S, Cin H, Hawkins C, Beck C, von Deimling A, Hans V, Brors B, Eils R, Scheurlen W, Blake J, Benes V, Kulozik AE, Witt O, Martin D, Zhang C, Porat R, Merino DM, Wasserman J, Jabado N, Fontebasso A, Bullinger L, Rucker FG, Döhner K, Döhner H, Koster J, Molenaar JJ, Versteeg R, Kool M, Tabori U, Malkin D, Korshunov A, Taylor MD, Lichter P, Pfister SM, Korbel JO. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. **Cell**. 2012;148(1-2):59-71.

Kühn MW, Radtke I, Bullinger L, Goorha S, Cheng J, Edelmann J, Gohlke J, Su X, Paschka P, Pounds S, Krauter J, Ganser A, Quessar A, Ribeiro R, Gaidzik VI, Shurtleff S, Krönke J, Holzmann K, Ma J, Schlenk RF, Rubnitz JE, Döhner K, Döhner H, Downing JR. High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. **Blood**. 2012;119(10):e67-75. Epub 2012 Jan 10. *Equal contribution

- Rücker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H, Habdank M, Kugler CM, Holzmann K, Gaidzik VI, Paschka P, Held G, von Lilienfeld-Toal M, Lübbert M, Fröhling S, Zenz T, Krauter J, Schlegelberger B, Ganser A, Lichter P, Döhner K, Döhner H. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. **Blood**. 2012;119(9):2114-21.
- Kayser S, Zucknick M, Döhner K, Krauter J, Köhne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, Rummel M, Germing U, Götze K, Nachbaur D, Schlegelberger B, Göhring G, Späth D, Morlok C, Teleanu V, Ganser A, Döhner H, Schlenk RF. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. **Blood**. 2012;119(2):551-8. Epub 2011 Nov 16.
- Lübbert M, Ruter B, Claus R, Schmoor C, Schmid M, Germing U, Kündgen A, Rethwisch V, Ganser A, Platzbecker U, Galm O, Brugger W, Heil G, Hackanson B, Deschler B, Döhner K, Hagemeijer A, Wijermans P, Döhner H. A multicenter phase II trial of Decitabine as first-line treatment of older AML patients judged unfit for induction chemotherapy. **Haematologica**. 2012;97(3):393-401. Epub 2011 Nov 4.

2011

- Döhner H, Gaidzik VI. Impact of genetic features on treatment decisions in AML. **Hematology Am Soc Hematol Educ Program**. 2011;2011:36-42.
- Russ AC, Sander S, Luck SC, Lang KM, Bauer M, Rucker FG, Kestler HA, Schlenk RF, Döhner H, Holzmann K, Döhner K, Bullinger L. Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA – target gene interactions in acute myeloid leukemia. **Haematologica**. 2011;96(12):1783-91.
- Kuchenbauer F, Mah SM, Heuser M, McPherson A, Ruschmann J, Rouhi A, Berg T, Bullinger L, Argiropoulos B, Morin RD, Lai D, Starczynowski DT, Karsan A, Eaves CJ, Watahiki A, Wang Y, Aparicio SA, Ganser A, Krauter J, Döhner H, Döhner K, Marra MA, Camargo FD, Palmqvist L, Buske C, Humphries RK. Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells. **Blood**. 2011;118(12):3350-3358.
- Krönke J, Schlenk RF, Jensen KO, Tschürtz F, Corbacioglu A, Gaidzik VI, Paschka P, Onken S, Eiwen K, Habdank M, Späth D, Lübbert M, Wattad M, Kindler T, Salih HR, Held G, Nachbaur D, von Lilienfeld-Toal M, Germing U, Haase D, Mergenthaler HG, Krauter J, Ganser A, Göhring G, Schlegelberger B, Döhner H, Döhner K. Monitoring of minimal residual disease in *NPM1* mutated acute myeloid leukemia: A study of the German-Austrian AML Study Group (AML SG). **J Clin Oncol**. 2011;29(19):2709-16.
- Kvinlaug BT, Chan WI, Bullinger L, Ramaswami M, Sears C, Foster D, Lazic SE, Okabe R, Benner A, Lee BH, De Silva I, Valk PJ, Delwel R, Armstrong SA, Döhner H, Gilliland DG, Huntly B. Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias. **Cancer Res**. 2011;71(12):4117-29.
- Gaidzik VI, Bullinger L, Schlenk RF, Zimmermann AS, Röck J, Paschka P, Corbacioglu A, Krauter J, Schlegelberger B, Ganser A, Späth D, Kündgen A, Schmidt-Wolf I, Götze K, Nachbaur D, Pfreundschuh M, Horst HA, Döhner H, Döhner K. *RUNX1* mutations in acute myeloid leukemia: Results from a comprehensive genetic and clinical analysis on 945 patients from the AML Study Group (AML SG). **J Clin Oncol**. 2011;29(10):1364-72.

- Taskesen E,* Bullinger L,* Corbacioglu A, Sanders M, Erpelinck CA, Wouters BJ, van der Poel-van de Luytgaarde S, Damm F, Krauter J, Ganser A, Schlenk RF, Lowenberg B, Delwel R, Döhner H, Valk PJ,* Döhner K.* Prognostic impact, concurrent genetic mutations and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML: further evidence for CEBPA double mutant AML as a distinctive disease entity. **Blood**. 2011;117(8):2469-75. *Equal contribution
- Kayser S, Döhner K, Krauter J, Köhne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, Kündgen A, Götze K, Rummel M, Nachbaur D, Schlegelberger B, Göhring G, Späth D, Morlok C, Zucknick M, Ganser A, Döhner H, Schlenk RF. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2,853 adult patients with newly diagnosed AML. **Blood**. 2011;117(7):2137-45.
- Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. **J Clin Oncol**. 2011;29(5):475-86.

2010

- Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. **Lancet**. 2010;376(9747):1164-74.
- Schlenk RF, Döhner K, Mack S, Stoppel M, Király F, Götze K, Hartmann F, Horst HA, Koller E, Petzer A, Grimminger W, Kobbe G, Glasmacher A, Salwender H, Kirchen H, Haase D, Kremers S, Matzdorff A, Benner A, Döhner H. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. **J Clin Oncol**. 2010;28(30):4642-8.
- Zenz T, Eichhorst B, Busch R, Denzel T, Häbe S, Winkler D, Bühler A, Edelmann J, Bergmann M, Hopfinger G, Hensel M, Hallek M, Döhner H, Stilgenbauer S. *TP53* mutation and survival in chronic lymphocytic leukemia. **J Clin Oncol**. 2010;28(29):4473-9.
- Lugthart S,* Gröschel S,* Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, Ossenkoppele GJ, Vellenga E, van den Berg-de Ruitter E, Schanz U, Verhoef G, Vandenberghe P, Ferrant A, Köhne CH, Pfreundschuh M, Horst HA, Koller E, von Lilienfeld-Toal M, Bentz M, Ganser A, Schlegelberger B, Jotterand M, Krauter J, Pabst T, Theobald M, Schlenk RF, Delwel R, Döhner K, Löwenberg B,* Döhner H.* Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. **J Clin Oncol**. 2010;28(24):3890-8. *Equal contribution
- Corbacioglu A,* Scholl C,* Schlenk RF, Eiwen K, Du J, Bullinger L, Fröhling S, Reimer P, Rummel M, Derigs HG, Nachbaur D, Krauter J, Ganser A, Döhner H, Döhner K. Prognostic impact of minimal residual disease in *CBFB-MYH11*-positive acute myeloid leukemia. **J Clin Oncol**. 2010;28(23):3724-9. *Equal contribution
- Dreger P, Döhner H, Ritgen M, Böttcher S, Busch R, Dietrich S, Bunjes D, Cohen S, Schubert J, Hegenbart U, Beelen D, Zeis M, Stadler M, Hasenkamp J, Uharek L, Scheid

C, Humpe A, Zenz T, Winkler D, Hallek MJ, Kneba M, Schmitz N, Stilgenbauer S. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the GCLLSG CLL3X trial. **Blood**. 2010 Jul 1. [Epub ahead of print].

Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst HA, Germing U, Döhner H, Döhner K. *IDH1* and *IDH2* mutations are frequent genetic alterations in acute myeloid leukemia (AML) and confer adverse prognosis in cytogenetically normal AML with *NPM1* mutation without *FLT3*-ITD. **J Clin Oncol**. 2010;28(22):3636-43.

Gröschel S,* Lugthart S,* Schlenk RF, Valk PJM, Eiwen K, Goudswaard C, van Putten WJL, Kayser S, Verdonck LF, Lübbert M, Ossenkoppele GJ, Germing U, Schmidt-Wolf I, Schlegelberger B, Krauter J, Ganzer A, Döhner H, Löwenberg B, Döhner K,* Delwel R.* High *EVI1* expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. **J Clin Oncol**. 2010;28(12):2101-7. *Equal contribution

Bullinger L, Ehrich M, Döhner K, Schlenk RF, Döhner H, Nelson MR, van den Boom D. Quantitative DNA-methylation predicts survival in adult acute myeloid leukemia patients. **Blood**. 2010;115(3):636-642.

Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. **Nat Rev Cancer**. 2010;10(1):37-50.

Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Löwenberg B, Bloomfield CD. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an International Expert Panel, on behalf of the European LeukemiaNet. **Blood**. 2010;115(3):453-474.

2009

Loeder S, Zenz T, Schnaiter A, Mertens D, Winkler D, Döhner H, Debatin KM, Stilgenbauer S, Fulda S. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. **Cancer Res**. 2009;69(23):8977-8986.

Zenz T, Häbe S, Denzel T, Mohr J, Winkler D, Bühler A, Sarno A, Groner S, Mertens D, Busch R, Hallek M, Döhner H, Stilgenbauer S: Detailed analysis of p53 pathway defects in fludarabine-refractory CLL: dissecting the contribution of 17p deletion, *TP53* mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. **Blood**. 2009;114(13):2589-2597.

Kayser S, Schlenk RF, Londono MC, Breitenbuecher F, Wittke K, Du J, Groner S, Späth D, Krauter J, Ganzer A, Döhner H, Fischer T, Döhner K, for the German-Austrian AML Study Group (AML SG). Insertion of *FLT3* internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. **Blood**. 2009;114(12):2386-2392.

Stilgenbauer S, Zenz T, Winkler D, Bühler A, Schlenk RF, Groner S, Busch R, Hensel M, Dührsen U, Finke J, Dreger P, Jäger U, Lengfelder E, Hohloch K, Söling U, Schlag R, Kneba M, Hallek M, Döhner H. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the GCLLSG. **J Clin Oncol**. 2009;27(24):3994-4001.

- Koreth J, Schlenk RF, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H, Appelbaum FR, Döhner H, Antin JH, Soiffer RJ, Cutler C. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: a systematic review and meta-analysis of 24 prospective clinical trials. **JAMA**. 2009;301:2349-61
- Gaidzik VI, Schlenk RF, Moschny S, Becker A, Bullinger L, Corbacioglu A, Krauter J, Schlegelberger B, Ganser A, Döhner H, Döhner K. Prognostic impact of *WT1* mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. **Blood**. 2009;113:4505-11.
- Schlenk RF,* Döhner K,* Kneba M, Götze K, Hartmann F, del Valle F, Kirchen H, Koller E, Fischer JT, Bullinger L, Habdank M, Späth D, Groner S, Krebs B, Kayser S, Corbacioglu A, Anhalt A, Benner A, Fröhling S, Döhner H. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia – results from AMLSG trial AML HD98B. **Haematologica**. 2009;94:54-60.
*Equal contribution.
- Madan V, Madan B, Brykczynska U, Zilbermann F, Hogeveen K, Döhner K, Döhner H, Weber O, Blum C, Rodewald HR, Sassone-Corsi P, Peters AH, Fehling HJ. Impaired function of primitive hematopoietic cells in mice lacking the mixed-lineage-leukemia homolog MLL5. **Blood**. 2009;113:1444-54.
- Zenz T, Mohr J, Eldering E, Kater AP, Buhler A, Kienle D, Winkler D, Dürig J, van Oers M, Döhner H, Stilgenbauer S. miR-34a as part of the chemotherapy resistance network in chronic lymphocytic leukemia. **Blood**. 2009;113:3801-8.
- Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Buchner T, Döhner H, Burnett AK, Lo-Coco F. Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. **Blood**. 2009;113:1875-91.

2008

- Fröhling S, Döhner H. Molecular origins of cancer: Chromosomal abnormalities in cancer. **N Engl J Med**. 2008;359:722-734.
- Bloomfield CD, Marcucci G, Döhner K, Döhner H. Acute myeloid leukemia. Introduction. **Semin Oncol**. 2008;35:324-5.
- Zenz T, Kröber A, Scherer K, Habe S, Bühler A, Benner A, Denzel T, Winkler D, Edelmann J, Schwaenen C, Döhner H, Stilgenbauer S. Mono-allelic TP53 inactivation is associated with poor prognosis in CLL: Results from a detailed genetic characterization with long term follow-up. **Blood**. 2008;112:3322-9.
- Schlenk RF,* Döhner K,* Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H, for the German-Austrian AML Study Group (AMLSG). Mutations and outcome of treatment in cytogenetically normal acute myeloid leukemia. **N Engl J Med**. 2008;358:1909-18.
*Equal contribution. Shared senior authorship
- Bullinger L, Döhner K, Kranz R, Stirner C, Fröhling S, Scholl C, Kim YH, Schlenk RF, Tibshirani R, Döhner H,* Pollack JR*: A FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. **Blood**. 2008;111:4490-528. *Shared senior authorship.
- Schmitt M, Schmitt A, Rojewski MT, Chen J, Giannopoulos K, Fei F, Yu Y, Götz M, Heyduk M, Ritter G, Speiser DE, Gnjatovic S, Guillaume P, Ringhoffer M, Schlenk RF,

Liebisch P, Bunjes D, Shiku H, Döhner H, Greiner J. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma elicits immunological and clinical responses. **Blood**. 2008;111:1357-65.

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Rai KR, Kipps TJ: Revised guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A Report from a Working Group sponsored by the International Workshop on Chronic Lymphocytic Leukemia (IWCLL). **Blood**. 2008;111:5446-56.

2007

Fröhling S,* Scholl C,* Levine RL, Loriaux M, Boggon TJ, Bernard OA, Berger R, Döhner H, Döhner K, Ebert BL, Teckie S, Golub TR, Schittenhelm MM, Lee BH, Griffin JD, Stone RM, Heinrich MC, Deininger MW, Druker BJ, Gilliland DG. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. **Cancer Cell** 12:501-13, 2007. *Equal contribution.

Bullinger L, Rücker FG, Kurz S, Du J, Scholl C, Sander S, Corbacioglu A, Lottaz C, Krauter J, Fröhling S, Ganser A, Schlenk RF, Döhner K, Pollack JR,* Döhner H*: Gene expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. **Blood** 110:1291-300, 2007. *Equal contribution.

Scholl C, Bansal D, Döhner K, Eiwen K, Huntly BJ, Lee BH, Rücker FG, Schlenk RF, Bullinger L, Döhner H, Gilliland DG, Fröhling S: The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis. **J Clin Invest** 117:1037-1048, 2007.

2006

Estey E, Döhner H: Acute myeloid leukemia (Seminar). **Lancet** 368:1894-1907, 2006.

Rücker FG,* Bullinger L,* Schwaenen C, Lipka DB, Wessendorf S, Fröhling S, Bentz M, Miller S, Scholl C, Schlenk RF, Radlwimmer B, Kestler HA, Pollack JR, Lichter P, Döhner K, Döhner H: Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. **J Clin Oncol** 24:3887-3894, 2006. *Equal contribution.

2005-

Döhner K*, Schlenk RF*, Habdank M, Scholl C, Rücker FG, Corbacioglu A, Bullinger L, Fröhling S, Döhner H: Mutant nucleophosmin (*NPM1*) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics – interaction with other gene mutations. **Blood** 106:3740-6, 2005. Epub 2005 Jul 28. *Equal contribution.

Fröhling S, Döhner H: Disruption of CEBPA function – A paradigm in myeloid leukemogenesis. **N Engl J Med** 351:2370-2372, 2004.

Bullinger L, Döhner K, Bair E, Fröhling S, Schlenk R, Tibshirani R, Döhner H, Pollack JR: Use of gene expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. **N Engl J Med** 350:1605-1616, 2004.

Schlenk RF, Fröhling S, Hartmann F, Fischer JT, Glasmacher A, del Valle F, Grimminger W, Götze K, Waterhouse C, Schoch R, Pralle H, Mergenthaler HG, Hensel M, Koller E, Kirchen H, Preiss J, Salwender H, Biedermann HG, Kremers S, Griesinger F, Benner A, Addamo B, Döhner K, Haas R, Döhner H: Phase III study of all-trans retinoic acid in

previously untreated patients 61 years or older with acute myeloid leukemia. **Leukemia** 18:1798-1803, 2004.

Fröhling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, Tobis K, Döhner H, Döhner K: *CEBPA* mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. **J Clin Oncol** 22:624-633, 2004. [Comment in **J Clin Oncol** 22:582-584, 2004].

Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, Schiffer CA, Döhner H, Tallman MS, Lister TA, Lo Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD: Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes and reporting standards for therapeutic trials in acute myeloid leukemia. **J Clin Oncol** 21:4642-4649, 2003.

Scherer SW, Cheung J, MacDonald JR, ... Döhner H, Döhner K, Rommens JM, Vincent JB, Venter JC, Li PW, Mural RJ, Adams MD, Tsui LC. Human chromosome 7: DNA sequence and biology. **Science** 300:767-772, 2003.

Stilgenbauer S, Döhner H: Campath-1H in a case of fludarabine-refractory chronic lymphocytic leukemia – Complete remission despite p53 gene mutation. **N Engl J Med** 347:452-453, 2002.

Döhner K, Tobis K, Ulrich R, Fröhling S, Benner A, Schlenk RF, Döhner H: Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years of age with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. **J Clin Oncol** 20:3254-3261, 2002.

Kröber A, Seiler T, Benner A, Bullinger L, Brückle E, Lichter P, Döhner H, Stilgenbauer S: V_H mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. **Blood** 100:1410-1416, 2002.

Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M, Lichter P: Genomic aberrations and survival in patients with chronic lymphocytic leukemia. **N Engl J Med** 343:1910-1916, 2000.

Stilgenbauer S,* Schaffner C,* Litterst A, Liebisch P, Gilad S, Bar-Shira A, James MR, Lichter P, Döhner H: Biallelic mutations in the *ATM* gene in T-prolymphocytic leukemia. **Nature Med** 3:1155-1159, 1997.

Döhner H, Stilgenbauer S, James MR, Benner A, Weilguni T, Bentz M, Fischer K, Hunstein W, Lichter P: 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. **Blood** 89:2516-2522, 1997.

Stilgenbauer S, Liebisch P, James MR, Schröder M, Schlegelberger B, Fischer K, Bentz M, Lichter P, Döhner H: Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.2-q23.1 in lymphoproliferative disorders. **Proc Natl Acad Sci USA** 93:11837-11841, 1996.